The Delhi High Court has granted an interim injunction against Zydus Lifesciences, an Ahmedabad-based drug maker, following a ...

FDA issues observations to Zydus oncology plant in Ahmedabad, company to address promptly with FDA.

Nuvama downgrades Zydus Lifesciences: Nuvama predicts a 10% drop in Zydus Lifesciences' stock; explore the reasons now!

Zydus Lifesciences Ltd has announced its entry into the global biologics contract development and manufacturing organization (CDMO) business through its plan to acquire Agenus Inc.'s US-based ...

Zydus acquires two Agenus biologics facilities in California for $75 million, expanding U.S. CDMO presence and securing rights to key cancer drug manufacturing.

Zydus Lifesciences plans to acquire US-based Agenus Inc, entering the global biologics CDMO market with two California facilities. The deal enhances Zydus’ biotech footprint, securing rights to ...

Agenus will give Zydus an exclusive licence for the development and commercialisation of BOT and BAL in Sri Lanka and India.

Zydus Lifesciences announced on Tuesday it is acquiring two biologics contract manufacturing facilities in California from US-based Agenus Inc for a total consideration of up to $125 million.

The agreement grants Zydus the rights to Agenus' next-generation immunotherapy platform, which is designed to enhance and sustain the immune system's fight against tumor cells.

The acquisition will establish Zydus' presence in fast growing global biologics CDMO space. Acquired capabilities include cutting-edge biologics development and manufacturing services to serve the ...

Agenus (NASDAQ:AGEN) stock surges 21% after partnering with Zydus Lifesciences for cancer therapies, botensilimab and balstilimab (BOT/BAL). Read more here.

Agenus announced it signed a partnership agreement with Zydus Lifesciences to expand patient access to Botensilimab and Balstilimab.